01/26/2026
‼️Please read the following letter coordinated by the American Society of Gene and Cell Therapy (ASGCT). The CYFIP2 Network has signed on in support of reauthorizing the Rare Pediatric Disease Priority Review Voucher (PRV) program.
“The PRV program has proven to be a powerful catalyst for therapeutic development. Since its creation, 63 PRVs have been awarded across 47 rare pediatric diseases. Prior to the creation of the program, only 4 of these 47 diseases had any FDA-approved treatments. Of the total 569 drug and biologic products granted rare pediatric disease designation between 2013 and 2022, 160 were gene therapies and 22 were antisense oligonucleotides (A*Os).”
ASGCT is proud to lead nonprofits, academic medical centers, and patient advocacy groups in urging Congress to pass the Mikaela Naylon Give Kids a Chance…